Fortrea Holdings (Fortrea Holdings) Debt-to-Equity : 0.97 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Fortrea Holdings Debt-to-Equity?

Fortrea Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $46 Mil. Fortrea Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,632 Mil. Fortrea Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,739 Mil. Fortrea Holdings's debt to equity for the quarter that ended in Dec. 2023 was 0.97.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Fortrea Holdings's Debt-to-Equity or its related term are showing as below:

FTRE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.02 Max: 0.97
Current: 0.97

During the past 4 years, the highest Debt-to-Equity Ratio of Fortrea Holdings was 0.97. The lowest was 0.02. And the median was 0.02.

FTRE's Debt-to-Equity is ranked worse than
87.04% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs FTRE: 0.97

Fortrea Holdings Debt-to-Equity Historical Data

The historical data trend for Fortrea Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortrea Holdings Debt-to-Equity Chart

Fortrea Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

N/A

0.02

0.97

Fortrea Holdings Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial					0.02	0.92	0.96	1.00	0.97

Competitive Comparison of Fortrea Holdings's Debt-to-Equity

For the Biotechnology subindustry, Fortrea Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fortrea Holdings's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortrea Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Fortrea Holdings's Debt-to-Equity falls into.

Fortrea Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Fortrea Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(45.6	+	1632.4)	/	1738.8
	=	0.97

Fortrea Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(45.6	+	1632.4)	/	1738.8
	=	0.97

Fortrea Holdings (NAS:FTRE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Fortrea Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Fortrea Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Fortrea Holdings (Fortrea Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (NAS:FTRE) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

K67:Germany

Address

8 Moore Drive, Durham, NC, USA, 27709

Website

https://www.fortrea.com

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Executives

Thomas Pike	officer: Chief Executive Officer	C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601
Peter M Neupert	director	13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005
Betty D Larson	director	GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE, CHICAGO IL 60661
R Andrew Eckert	director	THREE RAVINIA DRIVE, ATLANTA GA 30346
Edward A Pesicka	director	9120 LOCKWOOD BLVD, MECHANICSVILLE VA 23116
Amrit Ray	director	60 LEVERONI COURT, NOVATO CA 94949
Amanda M. Warren	officer: Chief Accounting Officer	8 MOORE DRIVE, DURHAM NC 27703
David Ross Smith	director	251 BALLARDVALE STREET, WILMINGTON MA 01887
Van Der Vaart Sandra D	director, officer: President and Secretary	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg	director, officer: Executive Vice President	P O BOX 1017, CHARLOTTE NC 28201-1017
James S. Hanson	officer: General Counsel	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Laboratory Corp Of America Holdings	10 percent owner	358 S MAIN ST, BURLINGTON NC 27215
Jill G. Mcconnell	officer: Chief Financial Officer	8 MOORE DRIVE, DURHAM NC 27703
Mark A. Morais	officer: Chief Operating Officer	8 MOORE DRIVE, DURHAM NC 27703
Robert S. Pringle	officer: Treasurer	531 SOUTH SPRING STREET, BURLINGTON NC 27215